TheraRadar
Clinical-Stage Companies / Rigel

Rigel

Pre-Approval PRO BETA
21
Total Trials
6
Phase 3
13
Phase 2
3
Recruiting
205
Score

Pipeline by Phase

Phase 3
6
Phase 2
13
Phase 1
2

Therapeutic Focus

Immune Thrombocytopenic Purpura Warm Antibody Autoimmune Hemolytic Anemia IGA Nephropathy Rheumatoid Arthritis Keratoconjunctivitis Sicca

Clinical Trials (21)

NCT02077192 Phase 3 COMPLETED

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Started: 10/1/2014

NCT04629703 Phase 3 COMPLETED

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Started: 3/25/2021

NCT03764618 Phase 3 COMPLETED

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Started: 4/24/2019

NCT04138927 Phase 3 ENROLLING BY INVITATION

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Started: 10/30/2019

NCT02076399 Phase 3 COMPLETED

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Started: 7/14/2014

NCT02076412 Phase 3 COMPLETED

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Started: 1/1/2015

NCT06161974 Phase 2 RECRUITING

Study of Olutasidenib and Temozolomide in HGG

Started: 2/1/2025

NCT02612558 Phase 2 COMPLETED

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

Started: 7/1/2016

NCT02112838 Phase 2 COMPLETED

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

Started: 10/1/2014

NCT00665626 Phase 2 COMPLETED

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

Started: 5/1/2008

NCT02040623 Phase 2 COMPLETED

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

Started: 3/1/2014

NCT01900249 Phase 2 COMPLETED

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

Started: 7/1/2013

NCT01591044 Phase 2 COMPLETED

A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma

Started: 7/1/2012

NCT00798096 Phase 2 COMPLETED

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

Started: 3/1/2009

NCT00665925 Phase 2 COMPLETED

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Started: 5/1/2008

NCT01597050 Phase 2 COMPLETED

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

Started: 8/1/2012

NCT02433236 Phase 2 WITHDRAWN

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

Started: 9/1/2015

NCT00752999 Phase 2 WITHDRAWN

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

Started: 11/1/2008

NCT05308264 Phase 1 RECRUITING

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Started: 9/12/2022

NCT01733992 Phase 1 COMPLETED

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Started: 11/1/2012

NCT07486713 Phase 4 RECRUITING

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Started: 2/23/2026

Drug Candidates

Olutasidenib CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates R906289 Monosodium (R289 Na) Olutasidenib + TMZ Fostamatinib Disodium Fostamatinib Fostamatinib disodium Fostamatinib 150 mg bid Fostamatinib 150 mg Fostamatinib 100 mg
Activity Status: Active
Last Trial Started: 2/23/2026
Last Trial Ended: 9/5/2022
Trials (12 months): 1
Completed Trials: 15
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.